Literature DB >> 11227727

Congenital deficiency of 11beta-hydroxysteroid dehydrogenase (apparent mineralocorticoid excess syndrome): diagnostic value of urinary free cortisol and cortisone.

M Palermo1, G Delitala, F Mantero, P M Stewart, C H Shackleton.   

Abstract

The syndrome of apparent mineralocorticoid excess (AME) is an inherited form of hypertension. This disorder results from an inability of the enzyme 11beta-hydroxysteroid dehydrogenase (11beta-OHSD) to inactivate cortisol to cortisone. The diagnosis of AME is usually based on an elevated ratio of cortisol to cortisone reduced metabolites in the urine [tetrahydrocortisol plus allotetrahydrocortisol to tetrahydrocortisone (THF+alloTHF/THE)]. The principal site of "A" ring reduction is the liver, but AME arises from mutation in the gene encoding 11beta-OHSD2 in the kidney. We used a gas chromatographic/mass spectrometric method to measure the urinary free cortisol (UFF) and free cortisone (UFE) in 24 patients affected by the two variants of AME [19 with the classical form (type I) and 5 with the mild form called AME type II] in order to provide a more reproducible in vivo measure of the renal enzymatic activity. Type I patients were divided into two groups: children under 12 and adults. UFF levels (microg/24 h) did not differ between under-12 controls and AME type I children (mean+/-SD, 9+/-4 and 15+/-12, respectively), but was significantly higher in affected adults compared to controls: (62+/-32 vs 29+/-8, p<0.01). No differences were found between adult controls and AME type II patients (29+/-8 and 37.0+/-14, respectively). UFE was undetectable in 63% of AME type I and significantly lower in AME type II (p<0.05). As a consequence UFF/UFE ratio was significantly higher in AME type I patients both in children and adults compared to controls (AME children: 5.1+/-2.6; normal children: 0.43+/-0.2, p<0.01; AME type I adults: 17.7+/-19.6; normal adults: 0.54+/-0.3 p<0.01). For AME type II, where UFE was detectable in every case, the UFF/UFE ratio was significantly higher than adult controls (2.75+/-1.5 vs 0.54+/-0.3, p<0.01). In conclusion, our study indicates that UFE and UFF/UFE ratio are sensitive markers of 11beta-OHSD2, directly reflecting the activity of the renal isozyme and readily identifying patients with AME. The presence of an altered UFF/UFE ratio in both types of AME, although with different degree of severity, calls for re-evaluation and the classification of AME as a single disorder.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11227727     DOI: 10.1007/bf03343803

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  26 in total

Review 1.  Apparent mineralocorticoid excess syndromes.

Authors:  M Shimojo; P M Stewart
Journal:  J Endocrinol Invest       Date:  1995 Jul-Aug       Impact factor: 4.256

2.  Pathogenesis of the type 2 variant of the syndrome of apparent mineralocorticoid excess.

Authors:  S Ulick; R Tedde; F Mantero
Journal:  J Clin Endocrinol Metab       Date:  1990-01       Impact factor: 5.958

3.  Apparent mineralocorticoid excess type II.

Authors:  F Mantero; R Tedde; G Opocher; P Dessi Fulgheri; G Arnaldi; S Ulick
Journal:  Steroids       Date:  1994-02       Impact factor: 2.668

4.  Quantitation of cortisol and related 3-oxo-4-ene steroids in urine using gas chromatography/mass spectrometry with stable isotope-labeled internal standards.

Authors:  M Palermo; C Gomez-Sanchez; E Roitman; C H Shackleton
Journal:  Steroids       Date:  1996-10       Impact factor: 2.668

5.  Mass spectrometry in the diagnosis of steroid-related disorders and in hypertension research.

Authors:  C H Shackleton
Journal:  J Steroid Biochem Mol Biol       Date:  1993-04       Impact factor: 4.292

Review 6.  A genetic defect resulting in mild low-renin hypertension.

Authors:  R C Wilson; S Dave-Sharma; J Q Wei; V R Obeyesekere; K Li; P Ferrari; Z S Krozowski; C H Shackleton; L Bradlow; T Wiens; M I New
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-18       Impact factor: 11.205

Review 7.  Expression of 11 beta-OHSD along the nephron of mammals and humans.

Authors:  S Kenouch; N Alfaidy; J P Bonvalet; N Farman
Journal:  Steroids       Date:  1994-02       Impact factor: 2.668

8.  Molecular basis for hypertension in the "type II variant" of apparent mineralocorticoid excess.

Authors:  A Li; R Tedde; Z S Krozowski; A Pala; K X Li; C H Shackleton; F Mantero; M Palermo; P M Stewart
Journal:  Am J Hum Genet       Date:  1998-08       Impact factor: 11.025

9.  Congenital 11 beta-hydroxysteroid dehydrogenase deficiency associated with juvenile hypertension: corticosteroid metabolite profiles of four patients and their families.

Authors:  C H Shackleton; J Rodriguez; E Arteaga; J M Lopez; J S Winter
Journal:  Clin Endocrinol (Oxf)       Date:  1985-06       Impact factor: 3.478

10.  Human hypertension caused by mutations in the kidney isozyme of 11 beta-hydroxysteroid dehydrogenase.

Authors:  T Mune; F M Rogerson; H Nikkilä; A K Agarwal; P C White
Journal:  Nat Genet       Date:  1995-08       Impact factor: 38.330

View more
  7 in total

1.  11-Beta Dehydrogenase Type 2 Activity Is Not Reduced in Treatment Resistant Hypertension.

Authors:  Lama Ghazi; Tanja Dudenbostel; Maria El Hachem; Mohammed Siddiqui; Chee Paul Lin; Suzanne Oparil; David A Calhoun
Journal:  Am J Hypertens       Date:  2017-05-01       Impact factor: 2.689

Review 2.  11β-hydroxysteroid dehydrogenases: intracellular gate-keepers of tissue glucocorticoid action.

Authors:  Karen Chapman; Megan Holmes; Jonathan Seckl
Journal:  Physiol Rev       Date:  2013-07       Impact factor: 37.312

3.  A Rare Cause of Chronic Hypokalemia with Metabolic Alkalosis: Case Report and Differential Diagnosis.

Authors:  Cristina Bertulli; Marguerite Hureaux; Chiara De Mutiis; Andrea Pasini; Detlef Bockenhauer; Rosa Vargas-Poussou; Claudio La Scola
Journal:  Children (Basel)       Date:  2020-11-05

4.  Improved Urinary Cortisol Metabolome in Addison Disease: A Prospective Trial of Dual-Release Hydrocortisone.

Authors:  Stéphanie Espiard; Johanna McQueen; Mark Sherlock; Oskar Ragnarsson; Ragnhildur Bergthorsdottir; Pia Burman; Per Dahlqvist; Bertil Ekman; Britt Edén Engström; Stanko Skrtic; Jeanette Wahlberg; Paul M Stewart; Gudmundur Johannsson
Journal:  J Clin Endocrinol Metab       Date:  2021-03-08       Impact factor: 5.958

5.  Detection of Urinary Exosomal HSD11B2 mRNA Expression: A Useful Novel Tool for the Diagnostic Approach of Dysfunctional 11β-HSD2-Related Hypertension.

Authors:  Domenica De Santis; Annalisa Castagna; Elisa Danese; Silvia Udali; Nicola Martinelli; Francesca Morandini; Mariangela Veneri; Lorenzo Bertolone; Oliviero Olivieri; Simonetta Friso; Francesca Pizzolo
Journal:  Front Endocrinol (Lausanne)       Date:  2021-08-23       Impact factor: 5.555

6.  Low renin hypertension.

Authors:  Manisha Sahay; Rakesh K Sahay
Journal:  Indian J Endocrinol Metab       Date:  2012-09

7.  Increased cortisol metabolism in women with pregnancy-related hypertension.

Authors:  Katarzyna Kosicka; Anna Siemiątkowska; Agata Szpera-Goździewicz; Mariola Krzyścin; Grzegorz H Bręborowicz; Franciszek K Główka
Journal:  Endocrine       Date:  2018-04-02       Impact factor: 3.633

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.